Therapy News and Research

RSS
Pemetrexed, paclitaxel regimens equally effective in NSCLC

Pemetrexed, paclitaxel regimens equally effective in NSCLC

Biosimulation and epilepsy treatments: an interview with Dr. Serge Bischoff, CEO of Rhenovia and RHENEPI program director

Biosimulation and epilepsy treatments: an interview with Dr. Serge Bischoff, CEO of Rhenovia and RHENEPI program director

Researchers explain why anti-tumor activity of specific immune cells suppress during tumor growth

Researchers explain why anti-tumor activity of specific immune cells suppress during tumor growth

electroCore’s non-invasive VNS therapy for headaches reviewed at AHS and NANS meetings

electroCore’s non-invasive VNS therapy for headaches reviewed at AHS and NANS meetings

Restricting antibiotics use unlikely to stop spread of drug resistance in typhoid fever

Restricting antibiotics use unlikely to stop spread of drug resistance in typhoid fever

State highlights: Union, Calif. Hospital Assn. at odds over organization, ballot issues; Ind. hospital cuts worry nurses; N.C. Medicaid overhaul changes

State highlights: Union, Calif. Hospital Assn. at odds over organization, ballot issues; Ind. hospital cuts worry nurses; N.C. Medicaid overhaul changes

Studies expose high prevalence of epilepsy and other neurological disorders in US Veterans

Studies expose high prevalence of epilepsy and other neurological disorders in US Veterans

Researchers develop new drug-eluting contact lens for prolonged delivery of glaucoma medication

Researchers develop new drug-eluting contact lens for prolonged delivery of glaucoma medication

Drugs that enhance oxidative stress kill rhabdomyosarcoma tumor cells

Drugs that enhance oxidative stress kill rhabdomyosarcoma tumor cells

Children hospitalized for pneumonia have similar outcomes with big gun antibiotics or penicillin

Children hospitalized for pneumonia have similar outcomes with big gun antibiotics or penicillin

Takeda presents clinical study results of oral proteasome inhibitor MLN9708 in multiple myeloma patients

Takeda presents clinical study results of oral proteasome inhibitor MLN9708 in multiple myeloma patients

Acetylon announces positive preclinical data of ricolinostat (ACY-1215) in models of lymphoma

Acetylon announces positive preclinical data of ricolinostat (ACY-1215) in models of lymphoma

ImmunoGen presents Phase I trial results of SAR650984 at ASH annual meeting

ImmunoGen presents Phase I trial results of SAR650984 at ASH annual meeting

Study offers new insight into benefits of vitamin D in people with multiple sclerosis

Study offers new insight into benefits of vitamin D in people with multiple sclerosis

ART safe and effective for treating combat-related symptoms of PTSD among veterans

ART safe and effective for treating combat-related symptoms of PTSD among veterans

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

New drug delivery system successfully treats advanced-stage ovarian cancer in mice

New drug delivery system successfully treats advanced-stage ovarian cancer in mice

Lawmakers close in on 'cease-fire' budget deal

Lawmakers close in on 'cease-fire' budget deal

Studies confirm superiority of Tasigna to Glivec at achieving molecular response in Ph+ CML patients

Studies confirm superiority of Tasigna to Glivec at achieving molecular response in Ph+ CML patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.